25.03.2024 - SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid (“CSF”) and plasma Tau proteins in Alzheimer’s patients. The additional Phase 1 SNK01 trial data suggest clinical activity regarding cognitive function in . Seite 1
19.10.2023 - SANTA ANA, Calif., Oct. 19, 2023 (GLOBE NEWSWIRE) - NKGen Biotech Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and . Seite 1